RANKL (Receptor activator of NFκB ligand)

The Cytokine Handbook

Volumn , Issue , 2003, Pages 871-883

  Blake, Simon ^a   James, Ian ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33646679574     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012689663-3/50041-7     Document Type: Chapter

References (76)

1. Akatsu T., Murakami T., Ono K., et al. Osteoclastogenesis inhibitory factor exhibits hypocalcemic effects in normal mice and in hypercalcemic nude mice carrying tumors associated with humoral hypercalcemia of malignancy. Bone 1998, 23:495-498.
2. Anderson D.M., Maraskovsky E., Billingsley W.L., et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997, 390:175-179.
3. Atkins G.J., Haynes D.R., Graves S.E., et al. Expression of osteoclast differentiation signals by stromal elements of giant cell tumors. J. Bone Miner. Res. 2000, 15:640-649.
4. Bachmann M.F., Wong B.R., Josien R., et al. TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation. J. Exp. Med. 1999, 189:1025-1031.
5. Bekker P.J., Holloway D., Nakanishi A., et al. The effect of a single dose of osteoprotegerin in post-menopausal women. J. Bone Miner. Res. 2001, 16:348-360.
6. Bucay N., Sarosi I., Dunstan C.R., et al. Osteo-protegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1988, 12:1260-1268.
7. Burgess T.L., Qian Y., Kaufman S., et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J. Cell Biol. 1999, 145:527-538.
8. Capparelli C., Kostenuik P.J., Morony S., et al. Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. Cancer Res. 2000, 60:783-787.
9. Cenci S., Weitzmann M.N., Roggia C., et al. Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. J. Clin. Invest. 2000, 106:1229-1237.
10. Chikatsu N., Takeuchi Y., Tamura Y., et al. Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro. Biochem. Biophys. Res. Commun. 2000, 267:632-637.
11. Dougall W.C., Glaccum M., Charrier K., et al. RANK is essential for osteoclast and lymph node development. Genes Dev. 1999, 13:2412-2424.
12. Emery J.G., McDonnell P., Burke M.B., et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem. 1998, 273:14363-14367.
13. Fata J.E., Kong Y.Y., Li J., et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 2000, 103:41-50.
14. Fazzalari N.L., Kuliwaba J.S., Atkins G.J., et al. The ratio of messenger RNA levels of receptor activator of nuclear factor kappa B ligand to osteoprotegerin correlates with bone remodeling indices in normal human cancellous bone but not in osteoarthritis. J. Bone Miner. Res. 2001, 16:1015-1027.
15. Firkin F., Schneider H., Grill V. Parathyroid hormone-related protein in hypercalcemia associated with hematological malignancy. Leuk. Lymphoma 1998, 29:499 ff.
16. Fuller K., Wong B., Fox S., et al. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J. Exp. Med. 1998, 188:997-1001.
17. Gao Y.H., Shinki T., Yuasa T., et al. Potential role of cbfa1, an essential transcriptional factor for osteoblast differentiation, in osteoclastogenesis: regulation of mRNA expression of osteoclast differentiation factor (ODF). Biochem. Biophys. Res. Commun. 1998, 252:697-702.
18. Gravallese E.M., Manning C., Tsay A., et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum. 2000, 43:250-258.
19. Hofbauer L.C., Gori F., Riggs B.L., et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 1999, 140:4382-4389.
20. Honore P., Luger N.M., Sabino M.A., et al. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord [see comments]. [erratum appears in Mat. Med. 2000 Jul;6(7):838]. Nat. Med. 2000, 6:521-528.
21. Horwood N.J., Kartsogiannis V., Quinn J.M., et al. Activated T lymphocytes support osteoclast formation in vitro. Biochem. Biophys. Res. Commun. 1999, 265:144-150.
22. Hsu H., Lacey D.L., Dunstan C.R., et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc. Natl. Acad. Sci. USA 1999, 96:3540-3545.
23. Huang L., Xu J., Kumta S.M., Zheng M.H. Gene expression of glucocorticoid receptor alpha and beta in giant cell tumour of bone: evidence of glucocorticoid-stimulated osteoclastogenesis by stromal-like tumour cells. Mol. Cell. Endocrinol. 2001, 181:199-206.
24. Hughes A.E., Shearman A.M., Weber J.L., et al. Genetic linkage of familial expansile osteolysis to chromosome 18q. Hum. Mol. Genet. 1994, 3:359-361.
25. Hughes A.E., Ralston S.H., Marken J., et al. Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat. Genet. 2000, 24:45-48.
26. Ikeda T., Kasai M., Utsuyama M., Hirokawa K. Determination of three isoforms of the receptor activator of nuclear factor-kappaB ligand and their differential expression in bone and thymus. Endocrinology 2001, 142:1419-1426.
27. Itonaga I., Fujikawa Y., Sabokbar A., et al. Rheumatoid arthritis synovial macrophage-osteoclast differentiation is osteoprotegerin ligand-dependent. J. Pathol. 2000, 192:97-104.
28. Jimi E., Akiyama S., Tsurukai T., et al. Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function. J. Immunol. 1999, 163:434-442.
29. Josien R., Li H.L., Ingulli E., et al. TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo. J. Exp. Med. 2000, 191:495-502.
30. Kartsogiannis V., Zhou H., Horwood N.J., et al. Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues. Bone 1999, 25:525-534.
31. Khosla S. Minireview: The OPG/RANKL/RANK system. Endocrinology 2001, 142:5050-5055.
32. Kitazawa R., Kitazawa S., Maeda S. Promoter structure of mouse RANKL/TRANCE/OPGL/ODF gene. Biochim. Biophys. Acta 1999, 1445:134-141.
33. Kodaira K., Mizuno A., Yasuda H., et al. Cloning and characterization of the gene encoding mouse osteoclast differentiation factor. Gene 1999, 230:121-127.
34. Kong Y.Y., Feige U., Sarosi I., et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999, 402:304-309.
35. Kotake S., Udagawa N., Takahashi N., et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J. Clin. Invest. 1999, 103:1345-1352.
36. Kotake S., Udagawa N., Hakoda M., et al. Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum. 2001, 44:1003-1012.
37. Kwon B., Youn B.S., Kwon B.S. Functions of newly identified members of the tumor necrosis factor receptor/ligand superfamilies in lymphocytes. Curr. Opin. Immunol. 1999, 11:340-345.
38. Lacey D.L., Timms E., Tan H.L., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176.
39. Lacey D.L., Tan H.L., Lu J., et al. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am. J. Pathol. 2000, 157:435-448.
40. Lam J., Nelson C.A., Ross F.P., et al. Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity. J. Clin. Invest. 2001, 108:971-979.
41. Li J., Sarosi I., Yan X.Q., et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc. Natl. Acad. Sci. USA 2000, 97:1566-1571.
42. Lum L., Wong B.R., Josien R., et al. Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. J. Biol. Chem. 1999, 274:13613-13618.
43. Mancino A.T., Klimberg V.S., Yamamoto M., et al. Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells. J. Surg. Res. 2001, 100:18-24.
44. Matsuzaki K., Udagawa N., Takahashi N., et al. Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. Biochem. Biophys. Res. Commun. 1998, 246:199-204.
45. Mizuno A., Murakami A., Nakagawa N., et al. Structure of the mouse osteoclastogenesis inhibitory factor (Ocif) gene and its expression in embryogenesis. Gene 1998, 215:339-343.
46. Morinaga T., Nakagawa N., Yasuda H., et al. Cloning and characterization of the gene encoding human osteoprotegerin/osteoclastogenesis-inhibitory factor. Eur. J. Biochem. 1998, 254:685-691.
47. Morony S., Capparelli C., Lee R., et al. A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1beta, TNF-alpha, PTH, PTHrP, and 1, 25(OH)2D3. J. Bone. Miner. Res. 1999, 14:1478-1485.
48. Nakagawa N., Kinosaki M., Yamaguchi K., et al. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem. Biophys. Res. Commun. 1998, 253:395-400.
49. O'Brien C.A., Gubrij I., Lin S.C., et al. STAT3 activation in stromal/osteoblastic cells is required for induction of the receptor activator of NF-kappaB ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1,25-dihydroxyvitamin D3 or parathyroid hormone. J. Biol. Chem. 1999, 274:19301-19308.
50. O'Brien E.A., Williams J.H., Marshall M.J. Osteoprotegerin ligand regulates osteoclast adherence to the bone surface in mouse calvaria. Biochem. Biophys. Res. Commun. 2000, 274:281-290.
51. Oyajobi B.O., Anderson D.M., Traianedes K., et al. Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy. Cancer Res. 2001, 61:2572-2578.
52. Price P.A., June H.H., Buckley J.R., Williamson M.K. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb. Vasc. Biol. 2001, 21:1610-1616.
53. Quinn J.M., Elliott J., Gillespie M.T., Martin T.J. A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. Endocrinology 1998, 139:4424-4427.
54. Romas E., Bakharevski O., Hards D.K., et al. Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis. Arthritis Rheum. 2000, 43:821-826.
55. Roodman G.D. Mechanisms of bone lesions in multiple myeloma and lymphoma. Cancer 1997, 80(8 Suppl. S):1557-1563.
56. Shevde N.K., Bendixen A.C., Dienger K.M., Pike J.W. Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc. Natl Acad. Sci. USA 2000, 97:7829-7834.
57. Simonet W.S., Lacey D.L., Dunstan C.R., et al. Osteoprotegerin-a novel secreted protein involved in the regulation of bone density. Cell 1997, 89:309-319.
58. Suda T., Takahashi N., Udagawa N., et al. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 1999, 20:345-357.
59. Takayanagi H., Iizuka H., Juji T., et al. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum. 2000, 43:259-269.
60. Tan K.B., Harrop J., Reddy M., et al. Characterization of a novel Tnf-like ligand and recently described Tnf ligand and Tnf receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells. Gene 1997, 204:35-46.
61. The American Society for Bone and Mineral Research Presidents Committee on Nomenclature Proposed standard nomenclature for new tumor necrosis factor family members involved in the regulation of bone resorption. J. Bone Miner. Res. 2000, 15:2293-2296.
62. Thomas R.J., Guise T.A., Yin J.J., et al. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 1999, 140:4451-4458.
63. Tomoyasu A., Goto M., Fujise N., et al. Characterization of monomeric and homodimeric forms of osteoclastogenesis inhibitory factor. Biochem. Biophys. Res. Commun. 1998, 245:382-387.
64. Tsuda E., Goto M., Mochizuki S., et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem. Biophys. Res. Commun. 1997, 234:137-142.
65. Whyte M.P., Hughes A.E. Expansile skeletal hyperphosphatasia is caused by a 15-base pair tandem duplication in TNFRSF11A encoding RANK and is allelic to familial expansile osteolysis. J. Bone Miner. Res. 2002, 17:26-29.
66. Whyte M.P., Mills B.G., Reinus W.R., et al. Expansile skeletal hyperphosphatasia: a new familial metabolic bone disease. J. Bone Miner. Res. 2000, 15:2330-2344.
67. Wiktor-Jedrzejczak W., Bartocci A., Ferrante A.W., et al. Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouse [erratum appears in Proc. Natl Acad. Sci. USA 1991 Jul 1;88(13):5937]. Proc. Natl Acad. Sci. USA 1990, 87:4828-4832.
68. Wong B.R., Josien R., Lee S.Y., et al. TRANCE (tumor necrosis factor (TNF)-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J. Exp. Med. 1997, 186:2075-2080.
69. Wong B.R., Josien R., Lee S.Y., et al. The TRAF family of signal transducers mediates NF-kappaB activation by the TRANCE receptor. J. Biol. Chem. 1998, 273:28355-28359.
70. Wong B.R., Josien R., Choi Y. TRANCE is a TNF family member that regulates dendritic cell and osteoclast function. J. Leukoc. Biol. 1999, 65:715-724.
71. Xu J., Tan J.W., Huang L., et al. Cloning, sequencing, and functional characterization of the rat homologue of receptor activator of NF-kappaB ligand. J. Bone Miner. Res. 2000, 15:2178-2186.
72. Yasuda H., Shima N., Nakagawa N., et al. Identity of osteoclastogenesis inhibitory factor (Ocif) and osteoprotegerin (Opg)-a mechanism by which Opg/Ocif inhibits osteoclastogenesis in vitro. Endocrinology 1998, 139:1329-1337.
73. Yasuda H., Shima N., Nakagawa N., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl Acad. Sci. USA 1998, 95:3597-3602.
74. Yoshida H., Hayashi S., Kunisada T., et al. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 1990, 345:442-444.
75. Yun T.J., Chaudhary P.M., Shu G.L., et al. OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. J. Immunol. 1998, 161:6114-6121.
76. Yun T.J., Tallquist M.D., Aicher A., et al. Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function. J. Immunol. 2001, 166:1482-1491.